Dr Osamu Iida (Kansai Rosai Hospital, Amagasaki, JP) discusses the 12-month outcomes from a Japanese post-market surveillance study that evaluated the device efficacy and safety in the clinical setting, after the launch of the GORE® VIABAHN® Endoprosthesis for the treatment of symptomatic peripheral arterial disease in the superficial femoral arteries.

Questions:
1. What is the background of the study?
2. What was the study designs?
3. What are the key results?
4. What conclusions can be made?
5. What are the take-home messages?
6. What are the next steps?

Recorded remotely from Amagasaki, 2021.

Editor: Mirjam Boros
Recording Editor: Tom Green